Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C_ASCENT
- 16 May 2019 Status changed from completed to discontinued.
- 07 Mar 2019 Results of substudy-A5335S presented at the 26th Conference on Retroviruses and Opportunistic Infections.
- 26 Nov 2018 Status changed from active, no longer recruiting to completed.